Table 2.
Response to asciminib subanalysis regarding baseline response.
| Resistant (9) | Intolerant (19*) | Total (29*) | |
|---|---|---|---|
| Best response to asciminib | |||
| All patients | |||
| CHRa | 9/9 (100%) | 19/19 (100%) | 29/29 (100%) |
| CCyRa | 3/9 (33%) | 16/19 (84%) | 19/29 (66%) |
| MMRa | 1/9 (11%) | 11/19 (58%) | 12/29 (41%) |
| MR4.5a | 0/9 (0%) | 4/19 (21%) | 4/29 (14%) |
| Patients without response at baseline | |||
| CCyRb | 3/9 (33%) | 5/8 (63%) | 8/17 (47%) |
| MMRb | 1/9 (11%) | 7/15 (47%) | 8/24 (33%) |
| MR4.5b | 0/3 (0%) | 4/19 (21%) | 4/29 (14%) |
*Due to short follow-up, 2 patients were excluded from response analysis.
CHR complete hematological response, CCyR complete cytogenetic response, MMR major molecular response, MR4.5 detectable disease with BCR-ABL1IS < 0.0032%.
aPatients with CHR, CCyR, MMR, or MR4.5 at baseline were evaluable for hematologic, cytogenetic, or molecular response and were considered responders if they maintained their response. bEvaluable patients without a CCyR, MMR, or MR4.5 at baseline.